NCT02350673 - A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 29, 2015

Primary Completion Date

December 16, 2019

Study Completion Date

December 16, 2019

Conditions

Solid Tumors

Interventions

DRUG

Atezolizumab

Participants will receive atezolizumab IV infusion at doses of 800 mg q2w or 1200 mg q3w.

DRUG

Cergutuzumab Amunaleukin

Participants will receive cergutuzumab amunaleukin IV infusion at escalated doses and at different dosing schedules in Part I and at MTD (or recommended dose) in Part II.

Trial Locations (14)

1011

CHUV; Departement d'Oncologie, Lausanne

2100

Rigshospitalet; Onkologisk Klinik, København Ø

2730

Herlev Hospital; Onkologisk afdeling, Herlev

10032

Columbia Univ Med Ctr, New York

10065

Memorial Sloan Kettering Cancer Center, New York

28050

START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid

31008

Clinica Universitaria de Navarra; Servicio de oncología, Pamplona

37203

SCRI-Tennessee Oncology, Nashville

46010

Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia

06520

Yale Cancer Center; Medical Oncology, New Haven

M5G 2M9

University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto

1066 CX

Antoni van Leeuwenhoek Ziekenhuis, Amsterdam

3015 GD

Erasmus MC, Rotterdam

08035

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY